投机快报

葉芬

這兩天會留意 DEAR 及 INCY，一有回調就會買進。

DEAR 價錢還OK。其他的如SNV，HBAN，RF，AIB - 已經起了很多了。

1.46 +0.15 (11.45%)
Mar 17 - Close
NASDAQ real-time data

Q4 (Dec '09)         2009
Net profit margin         50.05%         -168.24%
Operating margin         -15.00%         -141.91%
EBITD margin         -         -
Return on average assets         1.65%         -4.83%
Return on average equity         33.70%         -65.92%
Employees         201         -


XXXXXXXXXXXXXXXXX

INCY 一年的Chart 很漂亮。
價錢雖然是高了點。不過前景看起來很不錯。

http://bigcharts.marketwatch.com ... and=1385&mocktick=1


XXXXXXXXXXXXXXXXX

The Promise Behind Incyte
By Lisa LaMotta Mar 17, 2010 1:35 pm

Biotech investors should have Incyte (INCY) on their radar. Here’s why:

The drug discovery company will likely be announcing the results of a mid-stage study for an oral rheumatoid arthritis drug in April and analysts are pretty bullish on its prospects.

The drug program, currently referred to as INCB28050, or just '050, is similar to the later-stage drug '424 that Incyte is developing, which has already shown plenty of promise. While '424 is currently being tested in myelofibrosis, a bone marrow disease, and psoriasis, a condition that is closely related to rheumatoid arthritis, both drugs are Janus kinase (JAK) inhibitors. The JAK inhibitors target one or several of four enzymes that play a role in inflammatory diseases, myeloproliferative disorders, and malignancies.

The data that Incyte will be releasing soon is for a phase 2b study of '050 -- earlier data has been promising, but many investors are still a bit tentative about putting money on the program because of its infancy. They shouldn’t be though, because data from a '424 study in RA showed clear positive results for patients over a placebo. Cowen analyst Ziad Bakri told Minyanville that '050 is clearly efficacious.

XXXXXXXXXXXXXXXXXXXXXXXXX

Incyte (INCY) Turns into Gold.

Incyte Corporation (INCY) http://www.incyte.com/ currently trading in the $12.66 range on 2.5 million shares a day. INCY was trading in the $2 range a year ago and then made a steady, classic, textbook run up to its current level- headed for $13. There were a few very small dips and spikes along the way for INCY; but not many. INCY has a 52-week high of $12.62 set on 03-09-10. You don’t have to go on very much about INCY. It is what every pharma shareholder wants. It has a huge drug pipeline and management knows how to run the operation. Oppenheimer initiated coverage today with an ‘Outperform’ and I’m going with them; INCY is a long-term (1 Yr) ‘Buy’ consideration for me, even at its high. I just simply think the stock will continue to gain in value.

In mid-Feb, INCY posted a Q4 09 loss that was bigger than Q4 08, but that was because of a one-time non-cash charge of $34.3 million or $0.29 per share related to a mark-to-market adjustment in the value of the embedded derivative liability related to the 4.75% Convertible Senior Notes due 2015; and a non-cash expense of $4.7 million or $0.04 per share related to the amortization of the discount on the 4.75% Convertible Senior Notes. Clearing up debt is a sign of strength. In 2010 Guidance, INCY management said it expects revenues of $66 - $68 million, including $66 million of amortization of deferred revenue related to the Company’s collaborations with Novartis and Lilly.

葉芬

INCY

13.38 +0.39 (3.00%)
After Hours: 13.40 +0.02 (0.15%)
Mar 17, 5:50PM EDT


Posted on 03/17/10 at 11:41am by Daniel James Hayden IV

Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating for shares of Incyte Corporation (Nasdaq: INCY) with a price target in "in the high-teens".

They said that with an SPA from the FDA for the INCB18424 Phase III program, Incyte Corporation is well on its way to becoming a leading MF option in the U.S. market, with annual sales as high as $300 million.

Because investors are waiting on results from Incyte Corporation's Phase II 3 month data for INCB28050 in RA, the analysts listed five reasons that they expect positive INCB28050 Data in RA.

The Leerink Swann analysts wrote, "we believe a number of independent datapoints all point in the direction of ‘050 showing solid clinical activity in the RA setting. While this will be the first clinical database for this compound, INCY has been very clear that it’s JAK-inhibition profile is nearly identical to that of 18424, which makes the cumulative experience with the ‘424 compound highly relevant in predicting ‘050 activity. Here we outline the key features that give us high confidence that the Phase II 28050 program will show compelling activity in rheumatoid arthritis."

葉芬

DEAR - Dearborn Bancorp Inc. (NASDAQ)

Date        Open        High        Low        Last        Change        Volume        % Change
03/17/10        1.33        1.71        1.31        1.47        +0.16        957500        +12.21%

Composite Indicator        
   Trend Spotter TM        Buy        

Short Term Indicators        
   7 Day Average Directional Indicator        Buy        
   10 - 8 Day Moving Average Hilo Channel        Buy        
   20 Day Moving Average vs Price        Buy        
   20 - 50 Day MACD Oscillator        Buy        
   20 Day Bollinger Bands        Buy        

Short Term Indicators Average:          100% - Buy
20-Day Average Volume - 241175

Medium Term Indicators        
   40 Day Commodity Channel Index                Hold        
   50 Day Moving Average vs Price        Buy        
   20 - 100 Day MACD Oscillator        Buy        
   50 Day Parabolic Time/Price        Buy        

Medium Term Indicators Average:          75% - Buy
50-Day Average Volume - 558230

Long Term Indicators        
   60 Day Commodity Channel Index                Hold        
   100 Day Moving Average vs Price        Buy        
   50 - 100 Day MACD Oscillator        Buy        

Long Term Indicators Average:          67% - Buy
100-Day Average Volume - 308070

Overall Average:          88% - Buy

Price         Support         Pivot Point         Resistance
1.47         1.10         1.50         1.90

葉芬

INCY - Incyte Corporation (NASDAQ)

Date        Open        High        Low        Last        Change        Volume        % Change
03/17/10        13.05        13.44        12.85        13.38        +0.39        2145700        +3.00%

Composite Indicator        
   Trend Spotter TM        Buy        

Short Term Indicators        
   7 Day Average Directional Indicator        Buy        
   10 - 8 Day Moving Average Hilo Channel        Buy        
   20 Day Moving Average vs Price        Buy        
   20 - 50 Day MACD Oscillator        Buy        
   20 Day Bollinger Bands                Hold        

Short Term Indicators Average:          80% - Buy
20-Day Average Volume - 2144250

Medium Term Indicators        
   40 Day Commodity Channel Index        Buy        
   50 Day Moving Average vs Price        Buy        
   20 - 100 Day MACD Oscillator        Buy        
   50 Day Parabolic Time/Price        Buy        

Medium Term Indicators Average:          100% - Buy
50-Day Average Volume - 2628992

Long Term Indicators        
   60 Day Commodity Channel Index        Buy        
   100 Day Moving Average vs Price        Buy        
   50 - 100 Day MACD Oscillator        Buy        

Long Term Indicators Average:          100% - Buy
100-Day Average Volume - 3047865

Overall Average:          96% - Buy

Price         Support         Pivot Point         Resistance
13.38         12.63         13.22         13.81

tankangkai

回复 920# 葉芬


    哎呀，我守了它九个月了，之前上到12块没卖出，然后又掉到7块，心脏很难负荷，哈哈，卖出省下烦恼！

葉芬

回复  葉芬


    哎呀，我守了它九个月了，之前上到12块没卖出，然后又掉到7块，心脏很难负荷，哈哈， ...
tankangkai 发表于 18-3-2010 04:38 PM

   
有賺就好。 恭喜。

葉芬

INCY。。。


Biotech Can Still Be Healthy to Investors
Marketwire
March 18, 2010: 10:06 AM ET

http://money.cnn.com/news/newsfe ... ketwire/0598203.htm

Analysts from www.rothmanresearch.com have Incyte Corporation (NASDAQ: INCY) and Genzyme Corporation (NASDAQ: GENZ) on their radar. Here are reasons why: Incyte Corp is currently developing the later-stage drug '424, a drug program referred to as INCB28050, or just '050, which has already shown plenty of promise, plus they snugged an SPA from the FDA for the INCB18424 Phase III program. Meanwhile, Genzyme Corp recently declared the publication of phase III data on mipomersen in The Lancet. The data was published from a study that was conducted in patients with homozygous familial hypercholesterolemia (hoFH) and the results from an ongoing phase III study in patients with severe hypercholesterolemia are expected in mid-2010. To download the reports on Incyte Corporation and Genzyme Corporation register now for free at http://www.rothmanresearch.com/a ... 46/Mar-18-2010.html or
http://www.rothmanresearch.com/a ... 47/Mar-18-2010.html

With the recent economic downturn, the biotechnology industry has shown only a slump of one third of what the overall market has experienced. Small companies in this sector were the hardest hit due to funding issues and many are on the brink of financial ruin. With these readings, the chances of seeing a number of takeovers and mergers become apparent. Investors are always keen to see a successful merger or acquisition especially in this industry as this allows the smaller companies' shareholders to break a deal or help large corporate increase their product pipeline which can boost their share price.

Incyte Corporation delivered outstanding fourth quarter results which prove that company has serious growth potential. The company achieved all of their corporate goals in 2009 including the initiation of a global Phase III program for othei lead compound, INCB18424, for myelofibrosis, the completion of a successful corporate financing and the establishment of two major alliances with top-tier pharmaceutical firms. Consequently, they are in a strong position to advance their pipeline and prepare for the potential launch of INCB18424 in myelofibrosis.

While patient enrollment in the phase III trial for INCB18424 is complete in Europe, the US enrollment process is expected to be completed in the first quarter of 2010. Incyte is looking to file a New Drug Application in 2011, provided results from the trials are encouraging.

葉芬

18/3/2010

Somaxon Pharmaceuticals, Inc. (SOMX) - Shares of Somaxon Pharmaceuticals, Inc. continue to be the Top Stock Gainer of 2010 with the exception to Zanett. With such a high title, you have to continue to watch it.


  每天都在看她，可惜沒有買她。



FDA Approves NDA For Somaxon Pharma's Silenor For Treatment Of Insomnia - Quick Facts

FDA Approves NDA For Somaxon Pharma's Silenor For Treatment Of Insomnia - Quick Facts

Thu Mar 18 11:41:00 2010
EDT
(RTTNews) - Somaxon Pharma Inc. (SOMX) announced that U.S. FDA has approved the New Drug Application

for Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance.

Silenor is a low-dose oral tablet formulation of doxepin that is patent protected for use in insomnia.



Silenor is approved for the treatment of both short term and long term insomnia characterized by
difficulty with sleep maintenance in both adults and elderly patients.

The company noted that Silenor has not been designated as a controlled substance by the U.S. Drug
Enforcement Administration because of its demonstrated lack of abuse potential.

As result of the NDA approval for Silenor, Somaxon will be required to make a $1.0 million milestone
payment to its licensor for Silenor pursuant to its existing license agreement.

葉芬

Roberto小弟。。。SOMX 你有買到嗎？

6.47 +2.53 (64.21%)
Real-time:   2:25PM EDT

bennywt

somaxon pharma，有人中吗？？？昨天狂飙了。。。

葉芬

SOMX  

9.21 +5.27 (133.76%)
After Hours: 9.33 +0.12 (1.30%)
Mar 18, 7:59PM EDT

葉芬

19/3/2010


Economic Calendar Data - 3/19/10

None



Earnings Calendar - Companies Reporting Earnings - 3/19/10

Keryx Biopharmaceuticals, Inc. KERX - 8am EST -0.05 EPS

葉芬

19/3/2010

Top Stocks to Watch - March 19, 2010

Delta Petroleum Corp. (DPTR)

Premierwest Bancorp (PRWT)
Pacific Capital Bancorp (PCBC)

Star Scientific, Inc. (CIGX)

Borders Group, Inc. (BGP)

葉芬

19/3/2010


Somaxon Pharmaceuticals, Inc. (SOMX) - Shares of Somaxon Pharmaceuticals, Inc. soared on FDA Approval Thursday. The stock broke above $5.00 when it reopened and then broke through the $5.95 resistance level from 2008. Somaxon Pharmaceuticals, Inc a Top Stock Gainer of 2010 . With such a high title, you have to continue to watch it. Resistance is now located at $7.98 & $10.00.

Pacific Capital Bancorp (PCBC) - Shares of Pacific Capital Bancorp continue to climb higher on no recent news. PCBC closed above the 200 day moving average on Wednesday. This is a very bullish technical indicator.

Zanett Inc. (ZANE) - Shares of Zanett Inc. seem to have calmed down now, the volume is weak but still worth watching. Zanett has resistance located at $3.09 & $3.57. A close below $2.50 would be bearish.

葉芬

昨晚投機 APPA @ 2粒，希望她會和SOMX一樣，拿到FDA Approval。

AfterHours 她的Trading Halts， 今晚開市應該會知道消息了。
http://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts

2.06 +0.50 (32.05%)
After Hours: 2.19 +0.13 (6.31%)
Mar 18, 4:18PM EDT

bennywt

回复 935# 葉芬

祝你成功！！！这个药蛮不错的。。。

tankangkai

呜呜，
我的 PCX 和 SNV 昨晚都掉了！

bennywt

APPA沉了。。。

葉芬

只好拿票了。。等下一次的Application，年尾。

APPA

2.06 0.00 (0.00%)
Pre-market: 0.87 -1.19 (-57.77%)
Mar 19, 9:10AM EDT

tankangkai

回复 939# 葉芬


    你的买价是多少钱呢？